FDA approves Gilotrif® (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung

• Approval provides a new second-line treatment option for patients with the second largest sub-type   of non-small cell lung cancer (NSCLC), representing about 20-30% of NSCLC cases • Approval is based on results of the LUX-Lung 8 study, which showed significantly improved overall   survival and progression-free survival compared to Tarceva® (erlotinib) in patients with squamous cell  carcinoma of the lung • Gilotrif is already approved in more than 60 countries for the treatment of patients with distinct types  of EGFR mutation-positive NSCLC
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news